[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Advertisement

Springer Nature Link
Log in

Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls

  • Educational Series / Red Series
  • New Trends in Clinical Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The serum cancer antigen 125 (CA-125) remains a reliable biomarker in the therapeutic management of epithelial ovarian cancer (EOC). Monitoring the efficacy of cytotoxic chemotherapy (CT) and the early detection of relapse during the follow up of patients in remission represent the two most common clinical situations where the CA-125 has been successfully applied. There are however other scenarios along the course of the disease where the CA-125 can potentially aid in the decision-making process. Preoperative levels of CA-125 can help in selecting a subset of patients where an optimal cytoreduction may not be easily achieved. Perioperative variations in the CA-125 levels after primary surgery and, more importantly, the nadir value of the CA-125 after primary chemotherapy, are associated with patient outcome. This review focuses on the clinical relevance of dynamic changes in CA-125 levels during the primary treatment of EOC and its potential influence both in the patient management and in the design of clinical trials in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  2. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259

    Article  PubMed  Google Scholar 

  3. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529

    Article  PubMed  CAS  Google Scholar 

  4. Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15[Suppl 3]:274–281

    Article  PubMed  Google Scholar 

  5. Duffy MJ, Bonfrer JM, Kulpa J et al (2005) CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15:679–691

    Article  PubMed  CAS  Google Scholar 

  6. Gadducci A, Cosio S, Fanucchi A et al (2004) The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 93:131–136

    Article  PubMed  CAS  Google Scholar 

  7. Riedinger JM, Wafflart J, Ricolleau G et al (2006) CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol 17:1234–1238

    Article  PubMed  CAS  Google Scholar 

  8. Rocconi RP, Matthews KS, Kemper MK et al (2009) The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114:242–245

    Article  PubMed  CAS  Google Scholar 

  9. Rustin GJ, van der Burg ME, Griffin CL et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155–1163

    Article  PubMed  Google Scholar 

  10. Bast RC Jr (2010) CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116:2850–2853

    Article  PubMed  Google Scholar 

  11. Goonewardene TI, Hall MR, Rustin GJ (2007) Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 8:813–821

    Article  PubMed  Google Scholar 

  12. Vorgias G, Iavazzo C, Savvopoulos P et al (2009) Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 112:11–15

    Article  PubMed  Google Scholar 

  13. Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227–231

    Article  PubMed  CAS  Google Scholar 

  14. Gemer O, Segal S, Kopmar A (2001) Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 80:583–585

    Article  PubMed  CAS  Google Scholar 

  15. Cooper BC, Sood AK, Davis CS et al (2002) Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100:59–64

    Article  PubMed  CAS  Google Scholar 

  16. Saygili U, Guclu S, Uslu T et al (2002) Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 86:57–61

    Article  PubMed  Google Scholar 

  17. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R (2003) CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13:120–124

    Article  PubMed  CAS  Google Scholar 

  18. Obeidat B, Latimer J, Crawford R (2004) Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest 57:153–156

    Article  PubMed  Google Scholar 

  19. Barlow TS, Przybylski M, Schilder JM et al (2006) The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 16:496–500

    Article  PubMed  CAS  Google Scholar 

  20. Arits AH, Stoot JE, Botterweck AA et al (2008) Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 18:621–628

    Article  PubMed  CAS  Google Scholar 

  21. Gemer O, Lurian M, Gdalevich M et al (2005) A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 31:1006–1010

    Article  PubMed  CAS  Google Scholar 

  22. Alcazar JL, Miranda D, Unanue A et al (2004) CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. Int J Gynaecol Obstet 84:173–174

    Article  PubMed  CAS  Google Scholar 

  23. Brockbank EC, Ind TE, Barton DP et al (2004) Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 14:42–50

    Article  PubMed  CAS  Google Scholar 

  24. Mury D, Woelber L, Jung S et al (2011) Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol 137:1131–1137

    Article  PubMed  CAS  Google Scholar 

  25. Kang S, Kim TJ, Nam BH et al (2010) Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 101:13–17

    Article  PubMed  CAS  Google Scholar 

  26. Chi DS, Zivanovic O, Palayekar MJ et al (2009) A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 112:6–10

    Article  PubMed  CAS  Google Scholar 

  27. Kang S, Kim TJ, Seo SS et al (2011) Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol 120:18–22

    Article  PubMed  CAS  Google Scholar 

  28. Talbot RW, Jacobsen DJ, Nagorney DM et al (1989) Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 168:407–412

    PubMed  CAS  Google Scholar 

  29. van der Zee AG, Duk JM, Aalders JG et al (1990) The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol 97:934–938

    Article  PubMed  Google Scholar 

  30. Yoo SC, Yoon JH, Lyu MO et al (2008) Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer. J Gynecol Oncol 19:169–172

    Article  PubMed  Google Scholar 

  31. Zivanovic O, Sima CS, Iasonos A et al (2009) Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol 115:209–214

    Article  PubMed  CAS  Google Scholar 

  32. Rustin GJ, Vergote I, Eisenhauer E et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419–423

    Article  PubMed  Google Scholar 

  33. Crawford SM, Peace J (2005) Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16:47–50

    Article  PubMed  CAS  Google Scholar 

  34. Markman M, Liu PY, Rothenberg ML et al (2006) Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454–1458

    Article  PubMed  CAS  Google Scholar 

  35. Juretzka MM, Barakat RR, Chi DS et al (2007) CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 104:176–180

    Article  PubMed  CAS  Google Scholar 

  36. Prat A, Parera M, Peralta S et al (2008) Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 19:327–331

    Article  PubMed  CAS  Google Scholar 

  37. Kang S, Seo SS, Park SY (2009) Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol 100:244–247

    Article  PubMed  CAS  Google Scholar 

  38. van Altena AM, Kolwijck E, Spanjer MJ et al (2011) CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol 119:265–269

    Article  Google Scholar 

  39. Bast RC Jr, Klug TL, St John E et al (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887

    Article  PubMed  Google Scholar 

  40. Riedinger JM, Eche N, Basuyau JP et al (2008) Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol 109:194–198

    Article  PubMed  CAS  Google Scholar 

  41. Axtell AE, Lee MH, Bristow RE et al (2007) Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25:384–389

    Article  PubMed  Google Scholar 

  42. Mercado C, Zingmond D, Karlan BY et al (2010) Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 117:18–22

    Article  PubMed  Google Scholar 

  43. Harter P, Hilpert F, Mahner S et al (2009) Prognostic factors for complete debulking in first- and second-line ovarian cancer. Int J Gynecol Cancer 19[Suppl 2]:S14–17

    Article  Google Scholar 

  44. Zorn KK, Tian C, McGuire WP et al (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115: 1028–1035

    Article  PubMed  Google Scholar 

  45. Altundag K, Altundag O, Morandi P, Gunduz M (2005) CA125 nadir values as a prognostic factor in epithelial ovarian cancer. J Clin Oncol 23: 2435–2436; author reply 6

    Article  PubMed  Google Scholar 

  46. Tuxen MK, Soletormos G, Petersen PH, Dombernowsky P (2001) Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer. Clin Chem Lab Med 39:531–538

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology Centro Integral Oncologico Clara Campal, Hospital Universitario Madrid — Norte Sanchinarro, C/ Oña, 10, ES-28050, Madrid, Spain

    Iván Díaz-Padilla

  2. Division of Medical Oncology Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

    Iván Díaz-Padilla & Albiruni Ryan Abdul Razak

  3. Division of Gynecology Oncology, Hospital Universitario Madrid — Norte Sanchinarro, Madrid, Spain

    Lucas Minig

  4. Division of Gynecology Oncology Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

    Marcus Q. Bernardini

  5. Division of Medical Oncology, Hospital Universitario Vall d’Hebron, Barcelona, Spain

    Josep María del Campo

Authors
  1. Iván Díaz-Padilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albiruni Ryan Abdul Razak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucas Minig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcus Q. Bernardini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Josep María del Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iván Díaz-Padilla.

Additional information

Supported by an unrestricted educational grant from MSD Oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Díaz-Padilla, I., Razak, A.R.A., Minig, L. et al. Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. Clin Transl Oncol 14, 15–20 (2012). https://doi.org/10.1007/s12094-012-0756-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0756-8

Keywords

Search

Navigation